Published in Breast Cancer Res Treat on February 01, 2003
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 2.24
The multiple facets of periostin in bone metabolism. Osteoporos Int (2012) 2.03
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer (2006) 1.54
Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch (2011) 1.49
The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci (2013) 1.42
Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer. Dev Biol (2007) 1.35
EMT and tumor metastasis. Clin Transl Med (2015) 1.29
Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem (2008) 1.25
Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am J Physiol Renal Physiol (2008) 1.21
Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol Cancer (2007) 1.20
Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer (2010) 1.19
Secretome signature of invasive glioblastoma multiforme. J Proteome Res (2011) 1.13
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int (2014) 1.11
Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One (2011) 1.10
Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther (2013) 1.06
Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers. BMC Bioinformatics (2007) 1.04
Periostin-like-factor and Periostin in an animal model of work-related musculoskeletal disorder. Bone (2008) 0.98
Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS One (2013) 0.96
Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis (2013) 0.96
IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med (2010) 0.94
Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol (2007) 0.94
Targeting ECM Disrupts Cancer Progression. Front Oncol (2015) 0.92
Induction of periostin-like factor and periostin in forearm muscle, tendon, and nerve in an animal model of work-related musculoskeletal disorder. J Histochem Cytochem (2009) 0.91
Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping. J Cell Physiol (2010) 0.90
Relevance of periostin splice variants in renal cell carcinoma. Am J Pathol (2011) 0.88
Life stage differences in mammary gland gene expression profile in non-human primates. Breast Cancer Res Treat (2011) 0.87
Integrated extracellular matrix signaling in mammary gland development and breast cancer progression. Histol Histopathol (2014) 0.86
Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa). Int J Mol Sci (2015) 0.85
Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci (2014) 0.83
Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenviron (2010) 0.83
Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis. World J Gastroenterol (2015) 0.82
Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes. Proteomics Clin Appl (2008) 0.81
Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction. Oncotarget (2016) 0.79
Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway. PLoS One (2013) 0.79
Role of Periostin in Adhesion and Migration of Bone Remodeling Cells. PLoS One (2016) 0.79
Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer. PLoS One (2012) 0.78
Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer. J Nucl Med (2015) 0.78
Roles of periostin in symptom manifestation and airway remodeling in a murine model of allergic rhinitis. Allergy Asthma Immunol Res (2012) 0.78
Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol (2016) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature (2011) 3.37
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol (2006) 2.80
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell (2004) 2.27
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res (2009) 2.13
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res (2005) 2.13
Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park) (2011) 2.08
Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol (2005) 2.01
Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (2010) 2.00
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol (2008) 1.88
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia (2006) 1.84
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res (2003) 1.83
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med (2009) 1.79
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res (2004) 1.72
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69
Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res (2002) 1.69
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res (2006) 1.69
Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell (2002) 1.69
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem (2004) 1.64
c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell (2006) 1.64
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem (2005) 1.59
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest (2005) 1.58
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch (2007) 1.57
Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol (2006) 1.57
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle (2012) 1.56
Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood (2003) 1.56
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A (2010) 1.55
The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res (2006) 1.52
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis (2005) 1.48
Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal (2009) 1.47
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene (2002) 1.45
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44